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In this issue of Cell Stem Cell, Bao et al. demonstrate that Blimp1, which is required for primordial germ cell
(PGC) specification, is dispensable for the derivation of embryonic stem cells (ESCs), epiblast stem cells
(EpiSCs), and reprogramming. These findings argue that the acquisition of pluripotency does not require
a Blimp1-dependent PGC intermediate state.Pluripotency (from the Latin plurimus,
meaning very many, and potens, meaning
powerful) describes the special class of
cell types that have the power to generate
multiple cell lineages upon differentiation
(Figure 1). In this issue of Cell Stem Cell,
Bao et al. (2012) have provided another
fascinating piece to the puzzle of pluripo-
tency and reprogramming by examining
the role of the primordial germ cell (PGC)
determinant B lymphocyte induced matu-
ration protein 1 (Blimp1) in establishing
pluripotency in vitro. Blimp1 is a kruppel-
type zinc finger transcription factor highly
expressed in founder PGCs relative to the
surrounding somatic cells (Ohinata et al.,
2005). It is well established that a major
role for Blimp1 in PGC determination is
to repress somatic gene expression in
order to facilitate PGC fate (Kurimoto
et al., 2008; Ohinata et al., 2005), thus
leading to a tantalizing hypothesis that
Blimp1 may also act in reprogramming
to repress somatic cell fate and promote
pluripotency.
PGCs have fascinated biologists for
generations because of their special
status as embryonic progenitor cells that
ultimately differentiate through gameto-
genesis to eggs and sperm in the adult
organism. Arguably it is the humble PGC
that kick-started the field of pluripotency
in the 1950s through the pioneering
studies of Leroy Stevens and his work
on the ‘‘monster’’ tumor in the testis
known as the teratoma. Ultimately Dr.
Stevens uncovered the lurking pluripotent
potential of PGCs through his discovery
that testicular tetatomas consisting of
highly differentiated structures, including
teeth, hair, and skin, originate from
abnormal PGCs (Reganuss et al., 1982).
It should be noted that healthy PGCs
are not pluripotent in chimera assays(Wylie and Heasman, 1993). Instead,
cell-culture-induced reprogramming of
PGCs to embryonic germ cells (EGCs)
results in a cell type that is almost indistin-
guishable from pluripotent embryonic
stem cells (ESCs) (Sharova et al., 2007).
Since the technology for creating ESCs
and EGCs in mice was first established,
a range of pluripotent-like cells have
been derived (Figure 1). Similar to freshly
isolated PGCs, many of these cells exhibit
a barrier to pluripotency in the mouse
chimera assay, including epiblast stem
cells (EpiSCs) and FAB-SCs (Fibroblast
growth factor 2 (FGF2) Activin and Bio
derived stem cells) (Brons et al., 2007;
Chou et al., 2008). The translational signif-
icance of this work is that EpiSCs and
FAB-SCs are derived using conditions
similar to those involved in the growth
and maintenance of human ESCs and
human induced pluripotent stem cells,
suggesting that these cells may have an
inherent epigenetic barrier preventing
them from reaching their full potential.
Given the similarity between ESCs,
EGCs, and PGCs, it has been speculated
that self-renewing pluripotent cells de-
rived in a dish may all originate via a
PGC-like intermediate. In one of the stron-
gest arguments against this hypothesis,
Bao and colleagues made use of Blimp1
null mutant mice, which fail to fully specify
PGCs, yet progress normally through
blastocyst and epiblast stages (Ohinata
et al., 2005). In previous work this group
derived EpiSCs after carefully dissecting
epiblasts to remove the region containing
presumptive PGC precursors (Bao et al.,
2009). However, a nagging possibility
was that a few PGC precursors could
have remained. By using Blimp1 null
mutant mice and deriving ESCs from
blastocysts at e4.5 as well as EpiSCsCell Stemfrom postimplantation epiblast at e6.5,
the work of Bao et al. reveals unequivo-
cally that the Blimp1-dependent stage of
PGC development plays no role in estab-
lishing either cell type in vitro.
What about reprogramming? Classic
reprogramming experiments involve
starting with fibroblasts and inducing
pluripotency by retroviral transduction of
Oct4, Sox2, Klf4, and cMyc (Okita et al.,
2007). This alters the epigenome to create
iPSCs (Figure 1). As it turns out, the same
principles can also be applied to EpiSCs,
which are reprogrammed to pluripotent
rESCs by a change in the growth condi-
tions to ESC media plus LIF (Bao et al.,
2009) (Figure 1). Thus, toggling between
EpiSCs and rESCs provides a powerful
new model for identifying both barriers
and ways to enhance epigenetic reprog-
ramming. Putting this model to the test,
Bao et al. evaluated the role of Blimp1 in
epigenetic reprogramming of EpiSCs to
rESCs and determined that the dynamics
and efficiency of reprogramming are unaf-
fected in the absence of Blimp1. To prove
that the Blimp1 null rESCs are normal, an
elegant series of rescue experiments
using tetraploid blastocysts were per-
formed, revealing that Blimp1 null ESCs
were also capable of generating morpho-
logically normal embryos at e8.5. In an
elegant twist, the group went on to show
that the Blimp1 null rescued embryos
lacked the founder PGCs. Thus, the
work creatively came full circle to prove
that loss of Blimp1 is not a barrier to
epigenetic reprogramming and instead is
obligatory to the generation of founder
PGCs.
When all of this is taken together, it is
clear that PGCs have earned their rightful
place in history as being instrumental to
the field of pluripotency, and 60 yearsCell 11, July 6, 2012 ª2012 Elsevier Inc. 1
Figure 1. Murine Cell Types that Pass the Chimera Assay for Pluripotency
Shown are cell types that are either directly pluripotent in the murine chimera assay (green arrows) or must
first be reprogrammed to achieve chimeric pluripotency (red lines). Strategies for interconversion of the
various cell types are shown. Abbreviations: rESC, reprogrammed epiblast ESC-like cells; PGC, primor-
dial germ cell; EGC, embryonic germ cell; FAB-SC, Fibroblast growth factor 2 (FGF2) Activin and Bio
derived stem cells; FAB-SC stimulated, FAB-SC cultured with BMP4 and LIF; iPSC, induced pluripotent
stem cell.
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Previewslater we still have much to learn from
these very special cells. Here we learn
about a gene obligatory for PGC determi-
nation, but unnecessary for pluripotency
or reprogramming. Thus, repression of
somatic gene expression by Blimp1 is2 Cell Stem Cell 11, July 6, 2012 ª2012 Elseva PGC-specific phenomenon that most
likely requires molecular complexes that
operate uniquely in PGCs. This new
work out of the Surani laboratory is
grounded in ameticulous series of studies
by this group over the last decade ex-ier Inc.ploring the cell and molecular biology of
PGCs, pluripotency, and Blimp1, and we
look forward to the next fascinating piece
of the puzzle.REFERENCES
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